mixed amphetamine salts (Takeda)

Mydayis (mixed amphetamine salts) is a central nervous system (CNS) stimulant developed by Shire (now a subsidiary of Takeda) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged 13 years and older. It is a unique triple-bead extended-release formulation designed to provide symptom control for up to 16 hours with a single daily dose. The formulation contains four amphetamine salts: dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate, resulting in a 3:1 ratio of dextro- to levo-amphetamine. Its mechanism of action involves blocking the reuptake of norepinephrine and dopamine into the presynaptic neuron and increasing their release into the extraneuronal space. The triple-bead technology utilizes one immediate-release bead and two delayed-release beads that dissolve at different pH levels (5.5 and 7.0) to maintain steady plasma concentrations throughout the day.

Brand names

Mydayis

Other names

triple-bead mixed amphetamine saltsMAS